Understanding preserved autonomic function after multiple sclerosis
Official title: Deciphering Preserved Autonomic Function After Multiple Sclerosis
Run by Mayo Clinic · NCT07012135 · Data updated 2026-11-12
This project will test whether people with multiple sclerosis have preserved or abnormal blood pressure and other autonomic responses compared with uninjured controls.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 13 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | September 17, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | May 28, 2026 |
| Trial ID | NCT07012135 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–50 years old with a clinically confirmed diagnosis of multiple sclerosis (or healthy uninjured control volunteers) who do not have active cardiovascular, respiratory, peripheral neurological or autonomic disease, are not pregnant or lactating, have BMI under 35, and are not taking medications that interact with phenylephrine are ideal candidates.
✕Probably not a fit
People outside the 18–50 age range, those with active cardiovascular disease, diabetes or other autonomic/peripheral nervous system disorders, pregnant or lactating individuals, people with BMI ≥35, or those taking medications that interact with phenylephrine are unlikely to benefit or be eligible, and this project does not provide therapeutic treatment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will bring adults with clinically confirmed multiple sclerosis and uninjured control volunteers to a Mayo Clinic laboratory to perform detailed autonomic function tests focused on blood pressure regulation. Multiple parallel recordings will be taken during maneuvers that provoke sympathetic inhibition and activation, and tests related to skin blood flow and bladder-related autonomic control will be included. Participants with major cardiovascular, respiratory, peripheral neurological or autonomic disease, pregnancy or a BMI ≥35, or taking medications that interact with phenylephrine will be excluded. The goal is to map precise physiological metrics and see how they differ across a spectrum of autonomic function in people with and without MS.
Why it matters
Potential benefit: If successful, the work could identify objective physiological markers to detect autonomic problems earlier and help guide future personalized management of blood pressure and bladder issues in MS.
How similar studies have gone: Previous studies have documented autonomic dysfunction in multiple sclerosis, but combining high-precision, parallel laboratory recordings and targeted sympathetic inhibition/activation protocols is a relatively novel, more detailed approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18-50 years old * clinically confirmed diagnosis of multiple sclerosis -OR- uninjured control Exclusion Criteria: * symptoms of cardiovascular (including, but not limited to: hypertension, stroke, chest pain, etc.), respiratory, peripheral neurological or autonomic disease (particularly diabetes mellitus requiring treatment) * women who are pregnant or lactating * having a body mass index (BMI) ≥ 35 kg/m2 * taking or being administered a medication known to potentially have adverse interactions with phenylephrine * in the judgement of the principal investigator or clinical collaborator, any illness or condition that will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
Where it's running
-
Mayo Clinic
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Ryan J. Solinsky, MD — Mayo Clinic
- Study coordinator: Erin Lund
- Email: lund.erin@mayo.edu
- Phone: 507-284-9298
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
-
Cooling During Inpatient Rehab for People with MS
This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.